Clinical Trial Update: A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CD371-YSNVZIL-18 CAR T cells for acute myeloid leukemia; the trial is currently recruiting and includes relapsed or refractory AML.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD371-YSNVZIL-18 CAR T Cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING